Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CCKAR | P32238 | 3/20 | 0.36 |
| ▸ | CCKBR | P32239 | 3/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | LONP1 | P36776 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759439 | 0.97 | KISS1R (0.41) | KISS1RRENGNPATOPRD1OPRM1 | |
| SCHEMBL30759527 | 0.95 | OPRM1 (0.39) | KISS1ROPRD1OPRM1CTSLCTSB | |
| SCHEMBL31754278 | 0.94 | KISS1R (0.39) | KISS1RRENOPRD1OPRM1CTSL | |
| SCHEMBL31754333 | 0.93 | LONP1 (0.38) | CTSLCTSBMMP12LONP1 | |
| SCHEMBL30759443 | 0.92 | KISS1R (0.45) | KISS1RRENLONP1 | |
| SCHEMBL30759495 | 0.91 | MMP12 (0.38) | CTSLCTSBMMP12LONP1 | |
| SCHEMBL30759475 | 0.91 | PLG (0.35) | KISS1ROPRD1OPRM1CTSLCTSB | |
| SCHEMBL30759389 | 0.91 | KISS1R (0.42) | KISS1RRENGNPATOPRD1OPRM1 | |
| SCHEMBL30759393 | 0.90 | LMNA (0.38) | — | |
| SCHEMBL30759510 | 0.90 | MMP12 (0.37) | CTSLCTSBMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | KISS1R 2731/4885REN 186/4885GNPAT 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.